Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review

URN to cite this document:: urn:nbn:de:bvb:355-epub-455868
DOI to cite this document:: 10.5283/epub.45586

Huber, D. ; Seitz, S. ; Kast, K. ; Emons, G. ; Ortmann, Olaf

Preview

License: Creative Commons Attribution 4.0
PDF - Published Version
(511kB)

Date of publication of this fulltext: 28 Apr 2021 05:13

Alternative links to fulltext:DOI Publisher

This publication is part of the DEAL contract with Springer.

Details

Preview

Indexed in

Export bibliographical data

Abstract

Purpose BRCA mutation carriers have an increased risk of developing breast or ovarian cancer. Risk-reducing bilateral salpingo-oophorectomy (RRBSO) is associated with a decrease in risk for tubal and ovarian cancer. Hormone replacement therapy (HRT) may increase breast, ovarian, and endometrial cancer risk in the general population. This review analyses the published data on HRT and risk of ...